Ignite Creation Date:
2024-05-05 @ 9:36 AM
Last Modification Date:
2024-10-26 @ 9:01 AM
Study NCT ID:
NCT00000451
Status:
COMPLETED
Last Update Posted:
2013-01-29
First Post:
1999-11-02
Brief Title:
Drug Therapy for Alcohol Dependence in Alaska Natives NaltrexoneSertraline
Sponsor:
Yale University
Organization:
Yale University
Study Overview
Official Title:
Naltrexone and SSRI Therapy for Alcohol Dependence in Alaska Natives
Status:
COMPLETED
Status Verified Date:
2013-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This study will assess the ability of naltrexone Revia to reduce the risk of relapse in Alaska natives with alcohol dependence The study will also examine whether a combination of naltrexone and sertraline Zoloft yields better abstinence rates than naltrexone used alone Alaska Native individuals will be recruited into a 16 week outpatient study
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| R01AA012028 | NIH | None | httpsreporternihgovquickSearchR01AA012028 |